Looking to reinvent those troubled AAVs you've been reading about, investors back a $110M reboot effort
Next week, Affinia Therapeutics will present four new abstracts at the American Society of Gene and Cell Therapy. Though they bear obscure and academic names, they will provide the first proof of concept for an approach investors have now poured $170 million into and that Affinia wants to get in the clinic next year.
Affinia, a 2019 spinout from the lab of old Jim Wilson protégé Luk Vandenberghe, announced Monday that it raised a $110 million Series B led by the biotech VC EcoR1 Capital and the Tom Steyer hedge fund Farallon Capital. Thirteen other investors joined, including the blue-chip firms Atlas, RA Capital, Perceptive Advisors, Casdin Capital, F-Prime and GV.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,500+ biopharma pros reading Endpoints daily — and it's free.